Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.

IF 3.6 3区 医学 Q2 HEMATOLOGY
Juan Eirís, Juan Montoro, Marta Villalba, Pedro Chorão, Marina Pérez-Bravo, Nuria Rausell, Carla Satorres, Pedro Asensi Cantó, Inés Gómez-Seguí, Pilar Solves, Marta Santiago, Pilar Lloret-Madrid, Pablo Granados, David Martínez-Campuzano, Rafael Benavente, Alberto Louro, Paula Rebollar, Aurora Perla, Miguel A Sanz, Javier de la Rubia, Aitana Balaguer-Roselló, Jaime Sanz
{"title":"Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.","authors":"Juan Eirís, Juan Montoro, Marta Villalba, Pedro Chorão, Marina Pérez-Bravo, Nuria Rausell, Carla Satorres, Pedro Asensi Cantó, Inés Gómez-Seguí, Pilar Solves, Marta Santiago, Pilar Lloret-Madrid, Pablo Granados, David Martínez-Campuzano, Rafael Benavente, Alberto Louro, Paula Rebollar, Aurora Perla, Miguel A Sanz, Javier de la Rubia, Aitana Balaguer-Roselló, Jaime Sanz","doi":"10.1016/j.jtct.2024.10.009","DOIUrl":null,"url":null,"abstract":"<p><p>Gastrointestinal bleeding (GIB) is a serious complication following allogeneic hematopoietic stem cell transplantation (HSCT), with limited data on its incidence and characteristics, particularly for upper gastrointestinal bleeding (UGIB) of gastric origin. We aimed to evaluate the incidence, clinical, endoscopic, and histopathologic features, and outcomes of UGIB, with a focus on gastric vascular ectasias (GVEs) in patients undergoing HSCT with graft-versus-host disease (GVHD) prophylaxis using post-transplant cyclophosphamide (PTCY), sirolimus or calcineurin inhibitors, and mycophenolate mofetil. This retrospective, single-center study included all adult patients who underwent allogeneic HSCT at a single institution between January 2017 and December 2023. Data were collected on transplant procedures, complications, and GIB incidents, with UGIB cases undergoing endoscopic and histologic examination. Out of 559 patients, 38 (6.6%) experienced UGIB, with 27 cases (70%) attributed to GVE. GVE typically presented as melena or hematemesis at a median time of 68 d (range, 29 to 125) after transplant. Endoscopy revealed diffuse oozing from gastric antral mucosa without distinct lesions, while histology showed vascular congestion and mild foveolar hyperplasia. The 6-mo cumulative incidence of GVE was 5.1%. Older age (≥60 yr) and diagnosis of myelodysplastic/myeloproliferative neoplasm were significant risk factors. All cases resolved with no attributable mortality with supportive measures including transfusions, proton-pump inhibitors, and sirolimus withdrawal in some cases. GVE is a notable cause of UGIB in HSCT recipients on PTCY-based GVHD prophylaxis, presenting significant morbidity but favorable outcomes with appropriate management. The potential role of sirolimus and conditioning agents in GVE pathogenesis warrants further investigation.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtct.2024.10.009","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Gastrointestinal bleeding (GIB) is a serious complication following allogeneic hematopoietic stem cell transplantation (HSCT), with limited data on its incidence and characteristics, particularly for upper gastrointestinal bleeding (UGIB) of gastric origin. We aimed to evaluate the incidence, clinical, endoscopic, and histopathologic features, and outcomes of UGIB, with a focus on gastric vascular ectasias (GVEs) in patients undergoing HSCT with graft-versus-host disease (GVHD) prophylaxis using post-transplant cyclophosphamide (PTCY), sirolimus or calcineurin inhibitors, and mycophenolate mofetil. This retrospective, single-center study included all adult patients who underwent allogeneic HSCT at a single institution between January 2017 and December 2023. Data were collected on transplant procedures, complications, and GIB incidents, with UGIB cases undergoing endoscopic and histologic examination. Out of 559 patients, 38 (6.6%) experienced UGIB, with 27 cases (70%) attributed to GVE. GVE typically presented as melena or hematemesis at a median time of 68 d (range, 29 to 125) after transplant. Endoscopy revealed diffuse oozing from gastric antral mucosa without distinct lesions, while histology showed vascular congestion and mild foveolar hyperplasia. The 6-mo cumulative incidence of GVE was 5.1%. Older age (≥60 yr) and diagnosis of myelodysplastic/myeloproliferative neoplasm were significant risk factors. All cases resolved with no attributable mortality with supportive measures including transfusions, proton-pump inhibitors, and sirolimus withdrawal in some cases. GVE is a notable cause of UGIB in HSCT recipients on PTCY-based GVHD prophylaxis, presenting significant morbidity but favorable outcomes with appropriate management. The potential role of sirolimus and conditioning agents in GVE pathogenesis warrants further investigation.

干细胞移植中的胃出血:聚焦移植后环磷酰胺、西罗莫司和霉酚酸酯预防治疗下的胃血管异位。
背景与目的:消化道出血(GIB)是异基因造血干细胞移植(HSCT)后的一种严重并发症,有关其发生率和特征的数据有限,尤其是胃源性上消化道出血(UGIB)。我们旨在评估UGIB的发生率、临床、内镜和组织病理学特征及预后,重点是接受造血干细胞移植并使用移植后环磷酰胺(PTCY)、西罗莫司或钙神经蛋白抑制剂和霉酚酸酯预防移植物抗宿主病(GVHD)的患者的胃血管异位症(GVEs):这项回顾性单中心研究纳入了2017年1月至2023年12月期间在一家机构接受异基因造血干细胞移植的所有成年患者。研究收集了移植手术、并发症和GIB事件的数据,其中UGIB病例接受了内镜和组织学检查:在559例患者中,38例(6.6%)发生了UGIB,其中27例(70%)归因于GVE。GVE通常表现为中位时间为移植后68天(29-125天)的黑便或吐血。内镜检查显示胃前粘膜有弥漫性渗出,但无明显病变,组织学检查显示血管充血和轻度窝沟增生。6 个月的 GVE 累积发病率为 5.1%。年龄较大(≥60 岁)和诊断为骨髓增生异常/骨髓增生性肿瘤是重要的风险因素。所有病例在采取输血、质子泵抑制剂等支持性措施后均可治愈,无死亡病例,部分病例停用了西罗莫司:结论:GVE是造血干细胞移植受者在接受以PTCY为基础的GVHD预防性治疗时发生UGIB的一个重要原因,其发病率高,但如果处理得当,结果良好。西罗莫司和调节剂在GVE发病机制中的潜在作用值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
15.60%
发文量
1061
审稿时长
51 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信